Allergy Infusion: Xolair Is a Subcutaneous Injection, Not an IV Infusion
IMPORTANT DISAMBIGUATION: Allergy infusion is a misnomer. Searchers typically mean Xolair (omalizumab) — an anti-IgE biologic subcutaneous injection, NOT an IV infusion, despite patients recalling it as an 'infusion' because it is administered in a clinic under monitoring. There is no IV-infusion form of subcutaneous immunotherapy (SCIT). SCIT is a small 0.05-0.5 mL subcutaneous injection in the upper arm with a 26-27G needle per Cox 2011 PP3. Xolair was approved February 16, 2024 for IgE-mediated food allergy per OUtMATCH trial.
5 peer-reviewed sources
This page is about allergy infusion disambiguation: Xolair (omalizumab) is an anti-IgE biologic subcutaneous injection — NOT an IV infusion. There is no IV-infusion allergy immunotherapy product in the US. SCIT is a small subcutaneous shot in the upper arm, not an infusion.
The essentials
Allergy infusion is one of the most consequential disambiguation pages in allergy medicine: searchers using this term are overwhelmingly NOT looking for subcutaneous immunotherapy (SCIT) — they are almost always looking for Xolair (omalizumab), the anti-IgE biologic monoclonal antibody.
The 'infusion' misconception arises from a specific patient experience: Xolair is administered subcutaneously (under the skin) in a clinic or physician's office, requires monitoring for the first three doses for 60 minutes per FDA REMS requirements (then 30 minutes), and is given by a healthcare professional from a vial — all features that patients associate with an 'infusion.' In reality, Xolair is a subcutaneous injection (SC, not IV), using a standard needle at subcutaneous depth — similar to SCIT injections. Some early pre-approval Xolair trials did use intravenous administration, which may also contribute to the 'infusion' mental model. But the FDA-approved route is subcutaneous.
For absolute clarity: there is NO IV-infusion form of allergen immunotherapy (SCIT) on the US market. SCIT is a small subcutaneous injection (0.05-0.5 mL volume, 26-27G needle, 5/8 inch length typical) into the upper outer arm per Cox 2011 PP3 (JACI 2011;127[1 Suppl]:S1-S55). It is not an infusion.
Xolair (omalizumab, Genentech/Novartis) is an anti-IgE monoclonal antibody (FDA-approved 2003 for moderate-to-severe persistent allergic asthma; expanded to chronic spontaneous urticaria, CRSwNP, and most recently IgE-mediated food allergy in patients aged 1 year and older on February 16, 2024, following the OUtMATCH trial published in NEJM 2024). Xolair binds free IgE in the bloodstream, reducing the IgE available to arm mast cells and basophils. It does NOT induce allergen-specific tolerance — symptoms return when Xolair is discontinued, and it must be taken indefinitely every 2-4 weeks.
The other biologic injections sometimes confused with an 'allergy infusion': Dupixent (dupilumab, anti-IL-4Rα, FDA-approved March 2017) and Tezspire (tezepelumab-ekko, anti-TSLP, FDA-approved December 17, 2021) are also subcutaneous injections administered every 2 weeks and 4 weeks respectively.
Curex pairs at-home IgE testing with board-certified allergist review to identify allergen sensitization patterns — the same workup used to determine whether a patient is a candidate for SCIT, SLIT, or a biologic like Xolair. For eligible maintenance patients, the SCIT itself is delivered as one weekly self-administered shot at home for $129/month — a personalized serum sterile-compounded to USP <797> standards, with the first dose and every dose change supervised live over Zoom and a prescribed epinephrine auto-injector confirmed on hand (still a small subcutaneous injection, never an infusion).
How allergy shots retrain your immune system
SCIT (the actual 'allergy shot') works through a different mechanism than Xolair. SCIT uses allergen extract to retrain allergen-specific immunity through Treg cells and blocking IgG4 antibodies — producing durable post-treatment remission after the 3-5 year course. Xolair uses a monoclonal antibody to capture free IgE in the bloodstream, reducing mast-cell and basophil activation — effective for conditions driven by elevated IgE, but not inducing allergen-specific tolerance. The two are not interchangeable.
SCIT: subcutaneous allergen extract injection (0.05-0.5 mL, upper arm)
A small-volume injection of allergen extract into the subcutaneous tissue of the upper outer arm using a 26-27G needle. Build-up phase: weekly for 4-6 months. Maintenance: every 2-4 weeks for 3-5 years. 30-minute observation per Cox 2011 PP3. NOT an infusion.
Xolair (omalizumab): subcutaneous anti-IgE injection (not IV)
A subcutaneous injection of 75-375 mg omalizumab based on body weight and baseline IgE level, every 2-4 weeks in a clinic or physician's office. First three doses require 60-minute observation per FDA REMS. Not an IV infusion — same subcutaneous route as SCIT but with different extract (biologic antibody vs allergen).
The confusion: in-clinic monitoring creates 'infusion' mental model
Patients remember Xolair as an 'infusion' because it is given in a clinic by a professional, takes clinic time, and early clinical trials used IV administration. The FDA-approved route is SC. SCIT is also given in a clinic by a professional and also requires clinic monitoring — but neither is an infusion.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
For patients trying to decide between the injectable allergy options — SCIT, Xolair, and other biologics — the key distinctions are mechanism, indication, and post-treatment durability.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (allergy shots — NOT an infusion) | |||||
Xolair (omalizumab — SC injection, not IV infusion) | |||||
SLIT drops (for aeroallergen tolerance) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For aeroallergen tolerance without weekly clinic visits, Curex delivers the allergy shot itself at home: a personalized SCIT serum sterile-compounded to USP <797> standards, prescribed by a board-certified allergist and self-administered as one weekly shot at home for $129/month. Your first dose and every dose change are supervised live over Zoom and a prescribed epinephrine auto-injector is confirmed on hand — a small subcutaneous shot, never an infusion, and no biologic injections required.
See if at-home shots are right for youFrequently asked questions
Is Xolair an infusion or injection?
Xolair (omalizumab) is a subcutaneous injection — NOT an intravenous infusion. The FDA-approved route of administration is subcutaneous (under the skin), using a standard needle. Xolair is injected in a clinic or physician's office every 2-4 weeks, which creates the impression of an 'infusion visit,' but the actual drug delivery is subcutaneous. Early pre-approval clinical trials used intravenous administration, which may also contribute to the 'infusion' mental model. Since FDA approval in 2003, Xolair has been subcutaneous only. The first three doses require 60-minute observation per FDA REMS; subsequent doses require 30-minute observation.
Is there an IV allergy shot or infusion available?
No. There is no FDA-approved intravenous allergy immunotherapy product in the United States. Subcutaneous immunotherapy (SCIT, the standard allergy shot) is delivered subcutaneously, not intravenously. Xolair, Dupixent, and Tezspire are all subcutaneous injections. The only IV-administered allergy-adjacent product is antivenom (such as ANAVIP for North American crotaline snakebite), which uses horse-derived antibodies to treat snake-venom envenomation — an entirely different clinical context. Patients expecting an IV 'allergy infusion' in a clinical allergy setting are experiencing a misconception, most commonly about Xolair.
What is Xolair used for in allergy treatment?
Xolair (omalizumab) is FDA-approved for four indications: (1) Moderate-to-severe persistent allergic asthma in patients aged 6 years and older with confirmed IgE sensitization to a perennial allergen not controlled by inhaled corticosteroids; (2) Chronic spontaneous urticaria (CSU) in patients aged 12 years and older uncontrolled by antihistamines; (3) Chronic rhinosinusitis with nasal polyps (CRSwNP) as add-on to intranasal steroids in adults; (4) IgE-mediated food allergy in patients aged 1 year and older, approved February 16, 2024, based on the OUtMATCH trial (Wood RA et al, NEJM 2024) showing 67% protection against peanut allergen reactions versus 7% placebo. Xolair dose is 75-375 mg SC q2-4 wk based on total IgE and body weight.
How does Xolair differ from allergy shots (SCIT)?
Xolair (omalizumab) and SCIT are fundamentally different interventions. SCIT uses allergen extract to train the immune system to tolerate specific allergens through regulatory T cells and blocking IgG4 antibodies — producing durable post-treatment remission lasting years after stopping. Xolair captures free IgE antibodies in the bloodstream, reducing the IgE available to arm mast cells and basophils — effective for conditions driven by elevated IgE, but providing no allergen-specific tolerance. When Xolair is stopped, free IgE recovers and symptoms return. SCIT has a defined 3-5 year course and post-treatment durability; Xolair requires indefinite ongoing injections.
Can Xolair replace allergy shots for food allergy?
Xolair and SCIT are indicated for different conditions and cannot replace each other in most situations. SCIT (allergy shots) is not a standard treatment for food allergies — oral immunotherapy (OIT) is the immunotherapy approach for food allergy, and SCIT for food allergy was largely abandoned after a 1992 peanut SCIT trial (Oppenheimer et al) had a fatality. Xolair (anti-IgE biologic) was FDA-approved February 16, 2024 for IgE-mediated food allergy based on the OUtMATCH trial, providing an approved pharmacological option for food-allergy patients who need broad multi-food protection. For aeroallergen allergy (pollens, dust mite, dander), SCIT or SLIT remains the disease-modifying standard.
What happens during a Xolair injection visit?
A Xolair injection visit involves a subcutaneous injection of 75-375 mg omalizumab (calculated based on body weight and baseline total IgE level) administered in a physician's office or clinic. For the first three doses, the FDA REMS program requires 60-minute observation after injection because of rare but serious adverse reactions including anaphylaxis and Churg-Strauss syndrome (eosinophilic granulomatosis with polyangiitis). After the first three doses, 30-minute observation is standard. Each injection itself takes only a few minutes; the clinic time is dominated by the observation period. Xolair is continued indefinitely because stopping leads to return of symptoms as free IgE levels recover.
Related Articles
Allergy Shots for Pollen: Who Qualifies | Curex Guide
Yes, allergy shots target pollen via SCIT. Cox 2011 candidacy threshold, FDA SLIT tablets, per-allergen efficacy, and Curex at-home shots — all covered.
Read moreAllergy Shots: The Complete Patient Guide to SCIT | Curex
Allergy shots (SCIT) are the only FDA-recognized disease-modifying allergy treatment. Learn who qualifies, how they work, and what alternatives exist.
Read moreAllergy Shot for Dog Allergies | Curex Human SCIT Guide
Yes, there is an allergy shot for humans allergic to dogs — but dog SCIT evidence is 'poor and conflicting.' 16.5% of patients may skip shots if Can f 5-monosensitized.
Read moreAllergy Desensitization: Which Treatment Type? | Curex
Allergy desensitization is active allergen-specific immunotherapy (SCIT or SLIT). Differs from passive immunotherapy and pharmacotherapy in mechanism.
Read moreAllergy Medicine Injection: SCIT vs Biologics vs Steroids | Curex
Allergy medicine injections include SCIT (allergen extract — not a drug), Xolair, Dupixent, and depot steroids. SCIT is the only option with 4-yr post-treatment remission per NEJM 1999.
Read moreAllergy Therapy: All Treatments Explained | Curex
Allergy therapy spans pharmacotherapy, SCIT shots, SLIT drops, and biologics. Only SCIT and SLIT modify the underlying disease. Learn which therapy fits your situation.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.